Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
复制标题
DOI：
--
复制
发表时间：
1998-06
期刊：
影响因子：
11.2
通讯作者：
L. Pfeffer;C. Dinarello;R. Herberman;B. Williams;E. Borden;R. Bordens;M. Walter;T. L. Nagabhushan;P. Trotta;S. Pestka
中科院分区：
文献类型：
--
作者：
L. Pfeffer;C. Dinarello;R. Herberman;B. Williams;E. Borden;R. Bordens;M. Walter;T. L. Nagabhushan;P. Trotta;S. Pestka
40年前，ifn首次被描述为有效的抗病毒药物，重组IFN-alpha2a和IFN-alpha2b仅在11年前被批准用于治疗毛细胞白血病。今天，α -干扰素在世界范围内被批准用于治疗各种恶性肿瘤和病毒学疾病。虽然ifn - α在治疗这些疾病中的确切作用机制尚不完全清楚，但在表征这种高度多效性细胞因子的物理化学和多种生物学特性方面取得了许多进展。在这里，我们回顾了ifn - α的抗病毒和免疫调节特性，ifn - α多亚基受体的性质以及信号转导的分子机制的最新进展。在可能的情况下，我们纳入了来自自然发生和非自然发生的合成基因的重组α - ifn的比较数据。我们还回顾了临床数据和不同来源的重组α - ifn在人体内的副作用和抗原性。这些后一个主题是临床感兴趣的，因为它们可能会影响这些不同产品的功效。希望我们对IFN的了解将促使我们进一步探索IFN- α的作用机制，从而为这种原型细胞因子提供新的应用，它的全部治疗潜力尚未实现。
IFNs were first described as potent antiviral agents 40 years ago, and recombinant IFN-alpha2a and IFN-alpha2b were approved for the treatment of hairy cell leukemia just 11 years ago. Today, alpha-IFNs are approved worldwide for the treatment of a variety of malignancies and virologic diseases. Although the exact mechanism of action of IFN-alpha in the treatment of such diseases is not fully understood, many advances have been made in the characterization of the physicochemical and diverse biological properties of this highly pleiotropic cytokine. Here we review recent developments in our understanding of the antiviral and immunoregulatory properties of IFN-alpha, the nature of the multisubunit IFN-alpha receptor, and the molecular mechanisms of signal transduction. Where available, we have included comparative data on recombinant alpha-IFNs derived from both naturally occurring and nonnaturally occurring synthetic genes. We also review clinical data and data on the side effects and antigenicity of different sources of recombinant alpha-IFNs in humans. These latter topics are of clinical interest, because they may potentially affect the efficacy of these various products. Hopefully, what is already known about IFN will prompt further exploration into the mechanism(s) of action of IFN-alpha and thus deliver new applications for this prototypic cytokine, whose full therapeutic potential is yet to be realized.